Fused hetero-hetero bicyclic compounds and methods of use thereof
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I), or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, W, X, Y, Z, and are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
1. A compound having one of the following structures (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii) or (Ij):
or a pharmaceutically acceptable salt, isotopic form, stereoisomer, tautomer or prodrug thereof, wherein:
R 1 is cycloalkyl, heterocyclyl, aryl or heteroaryl;
L is, at each occurrence, independently absent or a linker selected from the group consisting of —O—, —NR d —, —NR d C(═O)—, —NR d S(═O) 2 — and —S(═O) 2 —, wherein R d is H or C 1 -C 6 alkyl;
R 2a , R 2b , R 2c , and R 2d are independently H, amino, cyano, halo, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkylamino, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 3 -C 8 cycloalkyl, heterocyclylalkyl, C 2 -C 6 alkynyl, C 2 -C 6 alkenyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl, aminylcarbonyl, heteroaryl or aryl;
R a is, at each occurrence, independently H, amino, cyano, halo, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkylamino, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy; C 3 -C 8 cycloalkyl, heterocyclylalkyl, heterocyclylaminylalkyl, C 2 -C 6 alkynyl, C 2 -C 6 alkenyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl, aminylcarbonyl, heteroaryl or aryl;
R 3a and R 3b are, at each occurrence, independently H, —OH, —NH 2 , —CO 2 H, halo, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 2 -C 6 alkynyl, hydroxylalkyl, alkoxyalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl; or R 3a and R 3b join to form oxo, a carbocyclic ring or a heterocyclic ring; or R 3a is H, —OH, —NH 2 , —CO 2 H, halo, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 2 -C 6 alkynyl, hydroxylalkyl, alkoxyalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl, and R 3b joins with R 4b to form a carbocyclic or heterocyclic ring;
R 4a and R 4b are, at each occurrence, independently H, —OH, —NH 2 , —CO 2 H, halo, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 2 -C 6 alkynyl, hydroxylalkyl, alkoxyalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl; or R 4a and R 4b join to form oxo, a carbocyclic ring or a heterocyclic ring; or R 4a is H, —OH, —NH 2 , —CO 2 H, halo, cyano, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 2 -C 6 alkynyl, hydroxylalkyl, alkoxyalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl or aminylcarbonyl, and R 4b joins with R 3b to form a carbocyclic or heterocyclic ring;
L 2 is a bond or alkylene;
Q is C(═O)—, —C(═NR 7 )—, NR 8 C(═O)—, —S(═O) 2 — or —NR 8 S(═O) 2 —;
when is a double bond then R 5 and R 6 are each independently H, halo, cyano, carboxyl, C 1 -C 6 alkyl, alkoxycarbonyl, aminylalkyl, alkylaminylalkyl, aryl, heterocyclyl, heterocyclylalkyl, heteroaryl or hydroxylalkyl, or R 5 and R 6 join to form a carbocyclic, heterocyclic or heteroaryl ring;
represents a double or triple bond;
when is a triple bond then R 5 is absent and R 6 is H, C 1 -C 6 alkyl, aminylalkyl, alkylaminylalkyl or hydroxylalkyl;
R 7 is H, —OH, —CN or C 1 -C 6 alkyl; and
R 8 is H, C 1 -C 6 alkyl, hydroxylalkyl, aminoalkyl, alkoxyalkyl, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminylcarbonylalkyl, C 3 -C 8 cycloalkyl or heterocyclylalkyl.
2. The compound of claim 1 , wherein R 1 is substituted with halo, hydroxyl, C 1 -C 6 alkyl, cyano, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, alkylaminyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, phosphate, phosphoalkoxy, boronic acid, boronic acid ester, —OC(═O)R or C 1 -C 6 alkylcarbonyloxy, or combinations thereof, wherein R is C 1 -C 6 alkyl.
3. The compound of claim 1 , wherein R 1 has one of the following structures:
4. The compound of claim 1 , wherein R a is, at each occurrence, independently H, C 1 -C 6 alkyl, CF 3 , cyano, —C(═O)NH 2 ,
5. The compound of claim 1 , wherein Q is —C(═O)—.
6. The compound of claim 1 , wherein each of R 5 and R 6 are H.
7. The compound of claim 1 , wherein
has one of the following structures:
8. The compound of claim 1 , wherein L 2 is a bond.
9. The compound of claim 1 , wherein L is absent, —O—, —NH—, —NHC(═O)—, —NHS(═O) 2 — or —S(═O) 2 —.
10. The compound of claim 1 , wherein each R 3a , R 3b , R 4a and R 4b is H, or wherein at least one occurrence of R 3a , R 3b , R 4a or R 4b is C 1 -C 6 alkyl.
11. The compound of claim 1 , having one of the following structures:
12. A substantially purified atropisomer according to claim 1 .
13. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
14. A method for treatment of a cancer mediated by a KRAS, HRAS or NRAS G12C mutation, the method comprising administering an effective amount of the pharmaceutical composition of claim 13 to a subject in need thereof.
15. A method for inhibiting activity of a KRAS, HRAS or NRAS G12C mutant protein, the method comprising reacting the KRAS, HRAS or NRAS G12C mutant protein with the compound of claim 1 .
16. A method for inhibiting proliferation of a cell population mediated by a KRAS, HRAS or NRAS G12C mutant protein, the method comprising contacting the cell population with the compound of claim 1 .
17. A method for treating a cancer mediated by a KRAS, HRAS or NRAS G12C mutation in a subject in need thereof, the method comprising:
determining if the subject has a KRAS, HRAS or NRAS G12C mutation; and
if the subject is determined to have the KRAS, HRAS or NRAS G12C mutation, then administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 13 .
18. A method for preparing a labeled KRAS, HRAS or NRAS G12C mutant protein, the method comprising reacting the KRAS, HRAS or NRAS G12C mutant with a compound of claim 1 , to result in the labeled KRAS, HRAS or NRAS G12C protein.
19. A method for inhibiting tumor metastasis, the method comprising administering an effective amount of the pharmaceutical composition of claim 13 to a subject in need thereof, wherein the tumor comprises a KRAS, HRAS or NRAS G12C mutation.
20. The method of claim 14 , wherein the cancer is a hematological cancer, pancreatic cancer, MYH associated polyposis, colorectal cancer or lung cancer.